Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 40.46 CNY -1.77% Market Closed
Market Cap: ¥13B

Tibet Rhodiola Pharmaceutical Holding Co
Cash from Investing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Tibet Rhodiola Pharmaceutical Holding Co
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Cash from Investing Activities
-¥589.1m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sinopharm Group Co Ltd
HKEX:1099
Cash from Investing Activities
-¥3.2B
CAGR 3-Years
3%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Cash from Investing Activities
-¥4B
CAGR 3-Years
32%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Cash from Investing Activities
¥908.4m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China National Medicines Corp Ltd
SSE:600511
Cash from Investing Activities
-¥17.4m
CAGR 3-Years
51%
CAGR 5-Years
21%
CAGR 10-Years
11%
Huadong Medicine Co Ltd
SZSE:000963
Cash from Investing Activities
¥254.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tibet Rhodiola Pharmaceutical Holding Co
Glance View

Market Cap
13B CNY
Industry
Health Care

Tibet Rhodiola Pharmaceutical Holding Co., nestled in the sprawling and mystical landscape of Tibet, is a beacon of traditional Chinese medicine intertwined with contemporary pharmaceutical practices. The company's genesis lies in the rich, indigenous knowledge of the Rhodiola plant, revered for its supposed adaptogenic properties, which potentially aid in combating stress and fatigue. The plant flourishes in the harsh, high-altitude environment of the Tibetan Plateau, and Tibet Rhodiola has adeptly harnessed both its historical and geographical advantages to cultivate, extract, and process Rhodiola into various health products. These formulations, which range from dietary supplements to wellness solutions, reflect a marriage of ancient herbal wisdom with modern scientific methodologies. Central to the company's business model is its vertically integrated supply chain, which allows it to oversee and control every aspect of production—from the sustainable harvesting of Rhodiola to its research and development ventures. This integration not only ensures quality and efficacy but also fortifies the company's brand as a trustworthy entity within the competitive herbal supplements market. By expanding its distribution channels, Tibet Rhodiola has successfully entered both domestic and international markets, leveraging the rising global enthusiasm for natural and holistic healthcare solutions. This strategic movement feeds directly into its revenue system, which thrives on the growing demand for health products that claim to support vitality and resilience, mirroring the age-old allure of Tibetan medicinal practices.

Intrinsic Value
46.83 CNY
Undervaluation 14%
Intrinsic Value
Price ¥40.46

See Also

What is Tibet Rhodiola Pharmaceutical Holding Co's Cash from Investing Activities?
Cash from Investing Activities
-589.1m CNY

Based on the financial report for Dec 31, 2025, Tibet Rhodiola Pharmaceutical Holding Co's Cash from Investing Activities amounts to -589.1m CNY.

What is Tibet Rhodiola Pharmaceutical Holding Co's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-2%

The average annual Cash from Investing Activities growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been -2% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett